Corbus Pharmaceuticals reports Q4 EPS (78c), consensus ($1.26)
During the fourth quarter and into 2025, we made significant progress across our pipeline. Both of our oncology programs have been advancing ...
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update
CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western studyFast Track Designation granted by FDA for CRB-701 to ...
Corbus Pharmaceuticals (NASDAQ:CRBP) Receives Outperform Rating from Wedbush
Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at ...
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors
This was the stock's fourth consecutive day of losses.
Houston Chronicle12d
Corbus Pharmaceuticals: Q4 Earnings Snapshot
NORWOOD, Mass. (AP) — NORWOOD, Mass. (AP) — Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based ...
Yahoo Finance11d
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update
March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings ... we made significant progress across our pipeline. Both of our oncology programs (CRB-701 and CRB-601) have been advancing ...
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors
The stock's fall snapped a two-day winning streak.
Mena FN11d
Corbus Pharmaceuticals Reports Q4 And 2024 Financial Results And Provides A Corporate Update
Corbus Pharmaceuticals Holdings ... scientific approaches to well-understood biological pathways. Corbus' pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the ...